C4X DiscoveryC4X Discovery Holdings Ltd has received a €8m milestone payment from the French pharmaceutical company Sanofi for its preclinical IL-17A inhibitor. This payment is based on a licence agreement from 2021, under which the British company could receive up to €414m, including royalties.
Tag Archive for: Drug development
Dynamic42 GmbHJena-based organ-on-chip specialist Dynamic42 has inked a strategic partnership with Ohio Lumex Co., Inc. The Ohio-based company, which is an established provider of life science and analytics solutions, will exclusively distribute Dynamic42’s human 3D-sphaeroid-based organ-on-chip models in the U.S. and Canadian markets.
AI via FreepikSwedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.
Ovid Therapeutics - Jeremy LevinBy Jeremy Levin, D.Phil, MB BChir
marquetand - pixapay.comDanish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many properties afforded by protein disorder.
Vaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.
Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
Antibody engineering?The development of therapeutic antibodies is a time and cost intensive process. Biological and physicochemical properties of the lead molecules influence almost every step in the development. Investing into antibody engineering and lead optimisation during early development pays off in later steps and does not only accelerate the programme, but also increases the chance of success.
EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395
Jolt Capital contributed $20m to the BC Platforms’ data footprint expansion on November 8th.